Literature DB >> 15667570

Significance of Fas and Fas ligand in tuberculous lymphadenitis.

Tehmina Mustafa1, Stanley J Mogga, Sayoki G M Mfinanga, Odd Mørkve, Lisbet Sviland.   

Abstract

The Fas/Fas-ligand (FasL) system plays an important role in regulation of apoptosis and the immune response, and is exploited by mycobacteria to evade the immune response. This study was performed to investigate the distribution and levels of FasL and Fas in lymph node granulomas and sera of tuberculous lymphadenitis patients by immunohistochemistry and enzyme-linked immunosorbent assay. The validity of soluble Fas (sFas) or soluble FasL (sFasL) as a diagnostic tool was also examined. Levels of sFasL in serum were elevated among patients. The numbers of FasL stained cells in lymph node granulomas were higher than Fas. Children had significantly higher levels of sFasL as compared to adults. The human immunodeficiency virus (HIV)-tuberculosis (TB)-coinfected patients displayed no differences in the levels of sFasL or sFas compared with HIV-negative patients. The healthy controls from a high endemic tuberculosis country (having latent TB) had significantly higher levels of sFasL than from a country with no TB transmission. The sensitivity and specificity of the FasL and Fas test were low when compared with the culture results as the gold standard. However, by using histology as the gold standard, the sensitivity and specificity of the FasL test were increased to 66.7% and 100%, respectively, but for the Fas test remained low. In conclusion, sFasL and sFas cannot be used as diagnostic tests for tuberculous lymphadenitis. However, its utility in detecting latent TB and childhood tuberculous lymphadenitis remains to be evaluated. FasL seems to play a role in immune modulation and pathogenesis of TB. Modulators of Fas/FasL-mediated apoptosis may therefore be clinically useful.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15667570      PMCID: PMC1782080          DOI: 10.1111/j.1365-2567.2004.02080.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  46 in total

1.  Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment.

Authors:  A van Rie; R Warren; M Richardson; T C Victor; R P Gie; D A Enarson; N Beyers; P D van Helden
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

2.  The use of the paediatric tuberculosis score chart in an HIV-endemic area.

Authors:  Patrick Van Rheenen
Journal:  Trop Med Int Health       Date:  2002-05       Impact factor: 2.622

3.  Immunity to tetanus in male adults in Dar es Salaam, Tanzania.

Authors:  S Aboud; E F Lyamuya; E K Kristoffersen; R Matre
Journal:  East Afr Med J       Date:  2002-02

4.  Increased soluble Fas ligand concentration in tuberculous pleural effusion.

Authors:  S H Wu; J J Chu; C D Chiang
Journal:  J Formos Med Assoc       Date:  2001-01       Impact factor: 3.282

5.  A national audit of the laboratory diagnosis of tuberculosis and other mycobacterial diseases within the United Kingdom.

Authors:  F A Drobniewski; B Watt; E G Smith; J G Magee; R Williams; J Holder; J Ostrowski
Journal:  J Clin Pathol       Date:  1999-05       Impact factor: 3.411

6.  Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma.

Authors:  T Hara; H Tsurumi; M Takemura; H Goto; T Yamada; M Sawada; T Takahashi; H Moriwaki
Journal:  Am J Hematol       Date:  2000-08       Impact factor: 10.047

7.  Increased expression of fas ligand in human tuberculosis and leprosy lesions: a potential novel mechanism of immune evasion in mycobacterial infection.

Authors:  T Mustafa; T G Bjune; R Jonsson; R H Pando; R Nilsen
Journal:  Scand J Immunol       Date:  2001-12       Impact factor: 3.487

8.  Increased Bcl-2 and reduced Bax expression in infected macrophages in slowly progressive primary murine Mycobacterium tuberculosis infection.

Authors:  S J Mogga; T Mustafa; L Sviland; R Nilsen
Journal:  Scand J Immunol       Date:  2002-10       Impact factor: 3.487

9.  Pleural effusion and serum soluble fas-ligand levels are elevated in different clinical conditions.

Authors:  P S Wang; Y M Chen; Y L Hsieh; C F Yu; C M Tsai; R P Perng
Journal:  Lung       Date:  2002       Impact factor: 2.584

10.  Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma.

Authors:  P Redondo; T Solano; B VAzquez; A Bauza; M Idoate
Journal:  Br J Dermatol       Date:  2002-07       Impact factor: 9.302

View more
  5 in total

1.  Immunohistochemical analysis of cytokines and apoptosis in tuberculous lymphadenitis.

Authors:  Tehmina Mustafa; Stanley J Mogga; Sayoki G M Mfinanga; Odd Mørkve; Lisbet Sviland
Journal:  Immunology       Date:  2006-04       Impact factor: 7.397

2.  Modulation of cell death by M. tuberculosis as a strategy for pathogen survival.

Authors:  Markos Abebe; Louise Kim; Graham Rook; Abraham Aseffa; Liya Wassie; Martha Zewdie; Alimuddin Zumla; Howard Engers; Peter Andersen; T Mark Doherty
Journal:  Clin Dev Immunol       Date:  2011-01-04

3.  Cytokine and Chemokine Concentrations as Biomarkers of Feline Mycobacteriosis.

Authors:  C O'Halloran; L McCulloch; L Rentoul; J Alexander; J C Hope; D A Gunn-Moore
Journal:  Sci Rep       Date:  2018-11-23       Impact factor: 4.379

4.  Differential expression of mycobacterial antigen MPT64, apoptosis and inflammatory markers in multinucleated giant cells and epithelioid cells in granulomas caused by Mycobacterium tuberculosis.

Authors:  Tehmina Mustafa; Harald G Wiker; Odd Mørkve; Lisbet Sviland
Journal:  Virchows Arch       Date:  2008-02-12       Impact factor: 4.064

5.  Identification of Potential Biomarkers and Related Transcription Factors in Peripheral Blood of Tuberculosis Patients.

Authors:  Longxiang Xie; Xiaoyu Chao; Tieshan Teng; Qiming Li; Jianping Xie
Journal:  Int J Environ Res Public Health       Date:  2020-09-24       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.